Alice L. Walton School of Medicine’s Post

What causes cancer? Can it be prevented? What are the odds of survival today? ArteraAI's Tim Showalter, VP of Clinical Development, sat down with Medium's Savio P. Clemente, NBC-HWC, ACC, for a new interview series called, “5 Things Everyone Needs To Know About #Cancer”, discussing some of the biggest questions about the disease, as well as his journey from the University of Virginia School of Medicine to #ArteraAI. "The reason why I joined ArteraAI is that it provided an opportunity to make an even bigger impact for cancer globally and to touch more patients’ lives, while also improving their quality of life. It’s about ensuring that people are getting optimal therapies and making good cancer decisions." ➡️ Read the full interview: https://bit.ly/44Dlhoa #Oncology #ProstateCancer

Stand Strong Against Lung Cancer this November..... Lung cancer begins in normal lung cells that have been altered in such a way that they no longer behave like a normal cell. These abnormal cells grow in an uncontrolled fashion, causing harm or invading normal tissue, and may even spread to other parts of the body. Submit related work for Advances In Clinical And Medical Research Submit work online: https://lnkd.in/gdU5iHy Read out latest published work here: https://lnkd.in/dhntQ3Hi #clinical #medical #clinmed #openaccess #submitmanuscript #callforpaper #submitnow #manuscript

One of the goals David Braun, MD, PhD, and Patrick Kenney, MD, have is to learn something new from every case of #kidneycancer they see to better understand the disease. In this video, produced by Urology Times, Drs. Braun and Kenney talk about the unmet needs in kidney #cancer and what more needs to be done to help #patients. Yale School of Medicine | MJH Life Sciences®

Oncologists, are you ready to Connect the Dots in Oncology? e-Brain OncoVision is The virtual event you can't miss! This action-packed, insights-driven e-conference takes you on a deep dive into: 🎯Precision Oncology: Uncover the latest advancements in personalized medicine. 🎯Early Cancer Detection: Learn about cutting-edge technologies for early diagnosis. 🎯Nanomedicine: Explore the future of targeted therapies. 🎯Clinical Trials for Personalized Medicine: Shape the future of cancer treatment. And the best part? It's absolutely FREE to attend! ➡️Register Here: https://lnkd.in/dyfSCty2 Bonus: PharmaShots readers, get ready for an exclusive offer! As their media partner, we're giving away FREE e-booths to showcase your innovations. Don't miss this chance to: 🎯Network with leading experts and industry peers. 🎯Gain valuable insights and stay ahead of the curve. 🎯Showcase your work to a global audience. 🎯Register for FREE and claim your free e-booth today! Hurry, limited spots available! ⏰ #eBrainOncoVision #Oncology #PrecisionMedicine #EarlyDetection #Nanomedicine #ClinicalTrials #FreeEvent #FreeBooth #PharmaShots P.S. Share this post with your colleagues and spread the word!

Hot off the press, another publication in Journal of Medical Economics to add to our very long publications list (80 and counting...) We developed cost-consequences and budget impact models for blue light-guided cystoscopy with Hexvix in patients diagnosed with non-muscle-invasive bladder cancer in France. We found that the incremental costs of using Hexvix were minimal: €269 per procedure (∼10% increase overall) in a large public hospital, and €133 per procedure (5% increase overall) using a more targeted approach within a smaller private hospital. To read the paper: https://lnkd.in/eBHpZSzB #Publication #MedicalWriting #MarketAccess

Today, I am highlighting:   Selwyn M. Vickers, MD, is the President and CEO of Memorial Sloan Kettering Cancer Center (MSK). Dr. Vickers is an internationally recognized pancreatic cancer surgeon, pancreatic cancer researcher, and pioneer in health disparities research. He became the first African American to head MSK in 2022, Vickers had already filled other leadership roles, from president of the American Surgical Association to dean of the UAB Heersink School of Medicine in Birmingham, Alabama. He pursues this aim both in clinical care and academic research, and helped to establish such efforts as Enhancing Minority Participation in Clinical Trials (EMPaCT), a network that works to diversify biomedical studies, and the Center for Healthy African American Men, a first-ever academic-community collaboration to develop, implement, and evaluate interventions designed to improve African American men’s health. For further information on Selwyn M. Vickers, MD, FACS, click on the link below: https://lnkd.in/g5A_234G #parkinsonsdisease #yopd #Parkinsonsresources #Parkinsonsawareness  #Neurology  #brainhealth  #health  #healthandwellness  #wellness  #wpc #Parkinsons #BlackwithPD #AfricanAmericanwithPD #clinicaltrials  #pdmovers #parkinsonresearch #blackpd #100blackmen #100blackwomen #blacksororities #blackfraternities #naacp  #urbanleague #rainbowpush #blackcaucus #BlackExcellence #SIG-BlackDiaspora #AfricanAmericanwithPD #underservedcommunities #underengaged #PDawareness #BlackwithPD #AfricanAmericanwithPD

We are delighted to announce that the multidisciplinary team of investigators Drs. Omar Khan, M.D. Ph.D., Brian Shy, Chris Dvorak & Julia Chu have been selected to receive one of the CTMCT pilot awards for their research project “Development of a Novel “in-line” Manufacturing method for the Rapid, Cost-Effective, and “off-the-shelf” Production of Cellular Therapeutics”.   Engineered cellular therapeutics have transformed our ability to treat patients with cancer, yet challenges remain to improve the accessibility, applicability, and safety of these therapies. The goal of our study is to leverage mRNA and lipid nano particle technologies to enable single-day manufacturing of complex cellular therapies for patients in an out-patient setting.   #ctmct #celltherapies #cellulartherapy #transfusionmedicine #translationalresearch #UCSFLabMedicine UCSF DEPARTMENT OF PEDIATRICS cc-University of California, San Francisco

📢CALL FOR ABSTRACTS ❗ #CuttingEdgeLaryngology2024 brings together our profession to advance the cause of those with voice, swallowing and breathing problems by presenting the latest clinical, scientific, and technological advances in Laryngology, and we invite you to share your research. For full information and criteria for submitting an abstract visit: https://lnkd.in/esN39zP4 We are accepting abstracts in the following categories: ✔️Voice ✔️Dysphagia ✔️Airway stenosis ✔️Paediatric laryngology ✔️Neurolaryngology ✔️Early laryngeal cancer ✔️Basic sciences 📅The deadline for submitting is June 7th. 🔗https://lnkd.in/esN39zP4 #Laryngology #CuttingEdge #ClinicalResearch #AbstractSubmission

overdiagnosis an euphemism for harms due to non-necessary treatment for slow-growing breast cancers that would never have affected a woman’s quality or length of life if left undiagnosed. Harm is also about false-positive results leading to more imaging, biopsies and non-necessary procedures see also https://lnkd.in/eKvb9gPV https://lnkd.in/eFniQbXu

📢We are thrilled to announce that we have enrolled the first patient into our SONOBIRD pivotal trial! ☑️ Our SONOBIRD trial will compare use of SonoCloud-9® ultrasound device combined with carboplatin vs standard of care therapies in patients with first recurrence of glioblastoma ☑️The registration study aims to enrol 560 US and EU patients over next two years, with view to obtaining marketing authorization ☑️ The first two patients have been enrolled at Universitair Ziekenhuis Brussel by Dr Johnny Duerinck in the department of Prof. Dr. Michaël Bruneau and in close collaboration with the department of oncology of Prof. Dr. Bart Neyns “We feel privileged to have enrolled the first patient in the SONOBIRD clinical trial. The development of effective treatments against glioblastoma is limited, due to the BBB preventing most systemic drugs from reaching the brain parenchyma. By utilizing Carthera’s SonoCloud-9® device to temporarily open the BBB in the areas surrounding the tumor, we will be able to assess the effectiveness of carboplatin against existing treatments, with the aim of providing glioblastoma patients with better therapeutic options.” - Johnny Duerinck, neurosurgeon at Universitair Ziekenhuis Brussel You can read the full press release here👇 https://lnkd.in/eQZiYS4U #clinicaltrial #glioblastoma #oncology #neurology #BBB #medtech